The clinical relevance of plasma protein binding changes

Clinical Pharmacokinetics

Volumn 52, Issue 1, 2013, Pages 1-8

  Roberts, Jason A ^a,b   Pea, Federico ^c   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; ANTIINFECTIVE AGENT; AZTREONAM; CARBAMAZEPINE; CEFAZOLIN; CEFTRIAXONE; DAPTOMYCIN; DIAZEPAM; ERTAPENEM; FENTANYL; FLUCLOXACILLIN; LIDOCAINE; PHENYTOIN; PLASMA PROTEIN; TEICOPLANIN; WARFARIN;

ACIDITY; COMPARTMENT MODEL; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG METABOLISM; GLOMERULUS FILTRATION; HUMAN; HYPOALBUMINEMIA; KIDNEY CLEARANCE; MINIMUM INHIBITORY CONCENTRATION; PH; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TEMPERATURE SENSITIVITY; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BLOOD PROTEINS; BODY TEMPERATURE; DRUG MONITORING; HUMANS; HYDROGEN-ION CONCENTRATION; KIDNEY; KIDNEY FUNCTION TESTS; METABOLIC CLEARANCE RATE; PHARMACOKINETICS; PROTEIN BINDING;

EID: 84873050688     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-012-0018-5     Document Type: Review

References (52)

1. Namendys-Silva SA, Gonzalez-Herrera MO, Texcocano-Becerra J, Herrera-Gomez A. Hypoalbuminemia in critically ill patients with cancer: incidence and mortality. Am J Hosp Palliat Care. 2011;28(4):253-7.
2. Ensom MH. Comment: unbound drug concentration versus unbound drug fraction. Ann Pharmacother. 2002;36(4):731-2. (author reply 732).
3. Toutain PL, Bousquet-Melou A. Free drug fraction vs. free drug concentration: a matter of frequent confusion. J Vet Pharmacol Ther. 2002;25(6):460-3.
4. Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov. 2010;9(12):929-39.
5. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99-110.
6. Burton ME, Shaw LM, Schentag JJ, Evans WE. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. Baltimore: Lippincott Williams and Wilkins; 2006.
7. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother. 1991;35(10):1953-9.
8. Barbot A, Venisse N, Rayeh F, Bouquet S, Debaene B, Mimoz O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 2003;29(9):1528-34.
9. Roberts JA, Roberts MS, Semark A, Udy AA, Kirkpatrick CM, Paterson DL, et al. Antibiotic dosing in the 'at risk' critically ill patient: linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol. 2011;11:3.
10. Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981;29(5):650-7.
11. MacKichan JJ, Zola EM. Determinants of carbamazepine and carbamazepine 10,11-epoxide binding to serum protein, albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol. 1984;18(4):487-93.
12. Finfer S, Bellomo R, McEvoy S, Lo SK, Myburgh J, Neal B, et al. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the saline versus albumin fluid evaluation (SAFE) study. BMJ. 2006;333(7577):1044.
13. Ulldemolins M, Roberts JA, Wallis SC, Rello J, Lipman J. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother. 2010;65(8):1771-8.
14. Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents. 2009;33(5):432-6.
15. Douglas A, Altukroni M, Udy AA, Roberts MS, Taraporewalla K, Jenkins J, et al. The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. BMC Anesthesiol. 2011;11:5.
16. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother. 2001;47(4):421-9.
17. Pea F, Brollo L, Lugano M. Dal Pos L, Furlanut M. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration. Ther Drug Monit. 2001;23(5):587-8.
18. Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43(6):405-15.
19. Burney RG, DiFazio CA, Foster JA. Effects of pH on protein binding of lidocaine. Anesth Analg. 1978;57(4):478-80.
20. Hinderling PH, Hartmann D. The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit. 2005;27(1):71-85.
21. Paxton JW, Calder RL. Propranolol binding in serum: comparison of methods and investigation of effects of drug concentration, pH, and temperature. J Pharmacol Methods. 1983;10(1):1-11.
22. Kochansky CJ, McMasters DR, Lu P, Koeplinger KA, Kerr HH, Shou M, et al. Impact of pH on plasma protein binding in equilibrium dialysis. Mol Pharm. 2008;5(3):438-48.
23. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115-21.
24. Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37(2):125-8.
25. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf. 1995;12(4):227-33.
26. Swabb EA, Leitz MA, Pilkiewicz FG, Sugerman AA. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects. J Antimicrob Chemother. 1981;8 Suppl E:131-40.
27. Janicke DM, Cafarell RF, Parker SW, Apicella MA, Jusko WJ. Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother. 1985;27(1):16-20.
28. Dvorchik B, Sica D, Gehr T. Pharmacokinetics and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease [poster]. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, 2002. pp. 27-31.
29. Mohr JF 3rd, Ostrosky-Zeichner L, Wainright DJ, Parks DH, Hollenbeck TC, Ericsson CD. Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. Antimicrob Agents Chemother. 2008;52(5):1891-3.
30. Pletz MW, Rau M, Bulitta J, De Roux A, Burkhardt O, Kruse G, et al. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob Agents Chemother. 2004;48(10):3765-72.
31. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother. 2007;59(2):277-84.
32. Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, Bulitta JB, Holzgrabe U, Drusano GL, et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother. 2007;51(9):3290-7.
33. Taburet AM, Guibert J, Kitzis MD, Sorensen H, Acar JF, Singlas E. Pharmacokinetics of sodium fusidate after single and repeated infusions and oral administration of a new formulation. J Antimicrob Chemother. 1990;25 Suppl B:23-31.
34. Peter JD, Jehl F, Pottecher T, Dupeyron JP, Monteil H. Pharmacokinetics of intravenous fusidic acid in patients with cholestasis. Antimicrob Agents Chemother. 1993;37(3):501-6.
35. Outman WR, Nightingale CH, Sweeney KR, Quintiliani R. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob Agents Chemother. 1990;34(11):2114-7.
36. Tincani E, Mazzali F, Morini L. Hypoalbuminemia as a risk factor for over-anticoagulation. Am J Med. 2002;112(3):247-8.
37. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JP. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(22):2039-43.
38. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents. 2010;35(6):606-8.
39. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16.
40. Udy AA, Roberts JA, Dewaele JJ, Paterson DL, Lipman J. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents. 2012;39(6):455-7.
41. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney B, Ungerer J, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142(1):30-9.
42. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36(4):332-9.
43. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis. 2006;42(12):1764-71.
44. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009-34.
45. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol. 2011;12(12):2070-9.
46. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45(8):755-73.
47. Ulldemolins M, Roberts JA, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. Chest. 2011;139(5):1210-20.
48. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126.
49. Pea F, Pavan F, Furlanut M. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet. 2008;47(7):449-62.
50. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care. 2012;2(1):35.
51. Burian A, Wagner C, Stanek J, Manafi M, Bohmdorfer M, Jager W, et al. Plasma protein binding may reduce antimicrobial activity by preventing intra-bacterial uptake of antibiotics, for example clindamycin. J Antimicrob Chemother. 2011;66(1):134-7.
52. Tillement JP, Lhoste F, Giudicelli JF. Diseases and drug protein binding. Clin Pharmacokinet. 1978;3(2):144-54.